Complement Inhibitors for Traumatic Brain Injury

A single dose of C1-Inh (15.0 IU; Berinert^®; CSL Behring GmbH, Marburg, Germany) or 0.9% saline solution was administered, intravenously (i.v.), by the tail vein 1 h after the CCI injury; CR2-Crry (10 mg/kg) or phosphate-buffered saline (PBS) were administered, i.v., by the tail vein at 1 and 7 h post-CCI; and PMX205 (1 mg/kg, synthesized in-house^{19 (link)}) or 5% glucose vehicle solution were administered by i.p. injection at twice-daily intervals, commencing 1 h post-TBI over a 10-day period. The i.v. injections were performed with mice under isoflurane anaesthesia, and the i.p. injections were administered with mice restrained. Doses and administration times were based on the available literature documenting the effectiveness of each complement inhibitor, or the known half-life of the agent.^{10 (link),14 (link),20 (link)} Control mice received the equivalent amount of vehicle at each dosing interval.